Featured Poster: Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib through Week 48 in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Piliang and colleagues evaluate scalp, eyebrow, and eyelash hair regrowth in patients treated with ritlecitinib
By Dermsquared Editorial Team | June 16, 2023
Ritlecitinib is an oral JAK3/TEC family kinase inhibitor used for the treatment of alopecia areata in patients 12 years and older. In the ALLEGRO phase 2b/3 trial, ritlecitinib demonstrated significant improvements in the proportion of patients with Severity of Alopecia Tool (SALT) score ≤20 at week 24.
This poster presents a post hoc analysis evaluating sustained scalp, eyebrow, and eyelash hair regrowth over 48 weeks in ritlecitinib-treated patients who had a clinical response at week 24. There were 4 different doses studied, including 200 mg QD loading doses over 4 weeks followed by 30 or 50 mg QD, or 30 or 50 mg QD without a loading dose.
For those who achieved SALT score ≤20 at week 24, 85.2% to 100% maintained this score through week 48, depending on the dose.